Insider Selling: Teladoc Health, Inc. (NYSE:TDOC) COO Sells 6,053 Shares of Stock

Teladoc Health, Inc. (NYSE:TDOC) COO Michael Willem Waters sold 6,053 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $49,271.42. Following the sale, the chief operating officer now owns 74,214 shares in the company, valued at $604,101.96. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Teladoc Health Stock Performance

Teladoc Health stock traded down $0.34 during midday trading on Monday, reaching $7.61. 8,635,004 shares of the stock traded hands, compared to its average volume of 5,484,486. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -5.64 and a beta of 0.93. The firm has a fifty day moving average price of $9.88 and a two-hundred day moving average price of $13.61. The company has a current ratio of 3.82, a quick ratio of 3.74 and a debt-to-equity ratio of 0.67. Teladoc Health, Inc. has a fifty-two week low of $7.31 and a fifty-two week high of $26.00.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Oppenheimer reduced their price target on shares of Teladoc Health from $21.00 to $17.00 and set an “outperform” rating on the stock in a report on Thursday. TD Cowen lowered their price target on Teladoc Health from $15.00 to $9.00 and set a “hold” rating on the stock in a report on Thursday. Wells Fargo & Company cut their target price on shares of Teladoc Health from $17.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. JPMorgan Chase & Co. dropped their target price on shares of Teladoc Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 21st. Finally, Barclays dropped their target price on shares of Teladoc Health from $20.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday. Fourteen equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Teladoc Health currently has an average rating of “Hold” and an average target price of $14.44.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Teladoc Health by 11.8% in the 4th quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock worth $377,451,000 after purchasing an additional 1,855,480 shares during the period. Dimensional Fund Advisors LP lifted its stake in Teladoc Health by 25.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock valued at $82,636,000 after buying an additional 767,999 shares in the last quarter. Norges Bank purchased a new stake in shares of Teladoc Health in the 4th quarter valued at approximately $9,714,000. Pale Fire Capital SE purchased a new stake in shares of Teladoc Health during the fourth quarter worth $8,960,000. Finally, Mizuho Markets Americas LLC purchased a new stake in shares of Teladoc Health in the 2nd quarter valued at about $3,937,000. 76.82% of the stock is owned by institutional investors.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.